In a previous report, we have presented a fully human monoclonal agonistic antibody targeting TRAIL-R1 (TR1419), which could strongly induce apoptosis in a wide range of TRAIL-R1–expressing cancer cell lines, in the presence of crosslinking antibodies (Jin et al., 2009; Jin et al., 2010). Here, TNFRSF10A is linked to cancer.